Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Botox Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedMass General Brigham Health PlanPolicy N/A

    Neuromuscular Blockers: Botox, Daxxify, Dysport, Myobloc, and Xeomin

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs MassHealth prior authorization for Botox, Daxxify, Dysport, Myobloc, and Xeomin under the medical benefit, including covered indications, dose limits, prescriber requirements, prerequisite therapies, and continuation criteria. The medications are also available under the pharmacy benefit and require review under the applicable MassHealth pharmacy policy.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyNeuromuscular Blockers: Botox, Daxxify, Dysport, Myobloc, and Xeomin
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the diagnosis, requested dose and frequency, relevant age and weight information, prescriber specialty or consultation notes, and required prerequisite-treatment documentation.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Daxxify was added to the policy criteria.

    Botox overactive bladder criteria were expanded to include urinary urgency with or without incontinence, nocturia, and urinary frequency.

    Botox migraine prophylaxis criteria were revised to require migraine headache frequency and to clarify dosing and partial but incomplete response to a CGRP inhibitor for concomitant therapy.

    Off-label Botox criteria were added for trigeminal neuralgia, severe craniofacial hyperhidrosis, and escalated dosing in axillary hyperhidrosis.

    Thoracic outlet syndrome and ventral hernia were added as Botox indications.

    Concurrent calcitonin-gene-related peptide antagonist restrictions were added for Botox migraine therapy, and sialorrhea was added as a Myobloc indication.

    Pediatric upper-limb spasticity criteria were added, and the maximum dose for this indication increased from 1,000 units to 1,500 units.

    Chronic migraine reauthorization was revised to require a decrease in migraine frequency and/or severity.

    The requirement that members not concurrently use a calcitonin-gene-related peptide antagonist was removed.

    Off-label criteria were added for Botox treatment of myofascial pain syndrome, myofascial pelvic pain syndrome, trigeminal neuralgia, severe craniofacial hyperhidrosis, and escalated-dose axillary hyperhidrosis.

    Daxxify criteria were added, and Botox overactive bladder criteria were updated to include urinary urgency with or without incontinence, nocturia, and urinary frequency.

    Botox migraine prophylaxis criteria were revised to require migraine headache frequency, appropriate dosing, and partial but incomplete response to a CGRP inhibitor when concomitant therapy is considered.

    Dysport, Myobloc, and Xeomin criteria were updated to align age and indication requirements with their package inserts.

    Thoracic outlet syndrome and ventral hernia were added as Botox indications.

    Botox chronic migraine criteria were updated to require step therapy through a CGRP inhibitor and allow beta blockers as one of multiple step-through options.

    Adult Botox neurogenic bladder dysfunction or neurogenic detrusor overactivity criteria were updated to limit dosing to 300 units no more frequently than every 12 weeks.

    The off-label anal fissure indication was limited to Botox and Dysport with dosing limits, and the prior anal stenosis, chronic constipation, and encopresis indication was changed to pediatric chronic constipation.

    The off-label gastroparesis indication was limited to Botox with an erythromycin step-through trial, and recertification was revised to require a positive response to therapy.

    Xeomin upper-limb spasticity criteria no longer require that spasticity in members younger than 18 years not be caused by cerebral palsy.

    5Botulinum toxin products
    Prior authorizationUtilization management
    90 daysNew-plan-member treatment history window
    300 unitsAdult neurogenic bladder dose
    Case-by-caseReview of unlisted uses or excessive doses

    Coverage Criteria

    Initial Authorization Pathways

    Authorization may be granted when either pathway is met:

    ONE of the following authorization pathways

    • New-to-plan/current-treatment pathway

      • Member is new to the plan, evidenced by a coverage effective date of 90 days or less.
      • Medical records document that the member is currently receiving treatment with the requested drug, excluding treatment obtained as samples or through a manufacturer's patient assistance program.
    • Standard authorization pathway

    Botox General Labeled Indications

    Botox (onabotulinumtoxinA) is covered for labeled indications when ALL applicable criteria are met:

    ALL of the following

    • ONE of the following diagnoses

      • Strabismus and blepharospasms associated with dystonia, including essential blepharospasm and cranial nerve VII disorders/hemifacial spasm.
      • Focal dystonia, including cervical dystonia/spasmodic torticollis in members older than 16 years, spasmodic dysphonia, oromandibular dystonia.
      • Limb spasticity due to cerebral palsy, multiple sclerosis, other demyelinating central nervous system disease, or spinal cord injury.
      • Focal spasticity related to cerebrovascular accident, including hemorrhagic stroke, anoxia, or traumatic brain injury.
    • Dose is appropriate for the stated indication; for a child, the prescriber must provide the child's weight.

    Botox Migraine Prophylaxis

    Botox is covered for chronic migraine prophylaxis when ALL criteria are met:

    ALL of the following

    • Diagnosis of chronic migraine prophylaxis.
    • Prescriber is a neurologist, pain medicine/anesthesiology physician, or physical medicine and rehabilitation physician, or consult notes from one of these specialists are provided.
    • Migraine headache frequency is at least 15 days per month.>= 15 headache days/month
    • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following conventional preventive agents

      • Beta blocker, unless the member has concurrent depression, asthma/bronchospastic disease, COPD, peripheral vascular disease, Raynaud's disease, baseline hypotension or bradycardia, or pheochromocytoma.

    Botox Bladder Indications

    Botox is covered for overactive bladder and neurogenic bladder dysfunction/neurogenic detrusor overactivity when the applicable criteria below are met:

    ONE of the following indications

    • Overactive bladder

      • Diagnosis of overactive bladder, including urinary urgency with or without incontinence, nocturia, or urinary frequency.
      • Prescriber is a urologist or consult notes from a urologist are provided.
      • Inadequate response or adverse reaction to ONE, or contraindication to BOTH, of the following treatment combinations

        • Two anticholinergic medications, such as oxybutynin or tolterodine.
        • One anticholinergic medication and one beta-3 adrenergic receptor agonist, such as mirabegron.

    Botox Off-Label Indications

    Botox off-label use is covered when ALL criteria for the selected indication are met:

    ONE of the following indications

    • Achalasia/esophageal dysphagia

      • Diagnosis of achalasia or esophageal dysphagia.
      • Prescriber is a gastroenterologist or surgeon, or consult notes from one are provided.
      • ANY of the following

        • Member has failed a surgical option, such as pneumatic dilation, laparoscopic Heller myotomy with partial fundoplication, or peroral endoscopic myotomy (POEM).
        • Member is not a surgical candidate or is unwilling to undergo these procedures.

    Additional Botox Off-Label Indications

    Botox is covered for the following additional off-label indications when ALL criteria for the applicable indication are met:

    ONE of the following indications

    • Myofascial pain syndrome

      • Diagnosis of myofascial pain syndrome.
      • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following

        • Cyclobenzaprine.
        • Gabapentin or pregabalin.
        • Local anesthetic, such as a lidocaine patch.

    Product-Specific Criteria

    The following product-specific indications are covered when ALL criteria for the applicable product and indication are met:

    ONE of the following product-specific pathways

    • Daxxify (daxibotulinumtoxinA-lanm)—cervical dystonia/spasmodic torticollis

      • Diagnosis of cervical dystonia/spasmodic torticollis.
      • Member is at least 18 years of age.
      • Dose is appropriate for the stated indication and is no more than 500 units as a single dose.<= 500 units single dose
    • Dysport (abobotulinumtoxinA)—applicable indication

      • Cervical dystonia/spasmodic torticollis

    Xeomin Cervical Dystonia, Spasmodic Torticollis, or Blepharospasm

    Xeomin is covered for cervical dystonia, spasmodic torticollis, or blepharospasm when ALL criteria are met:

    ALL of the following

    • ONE of the following diagnoses

      • Cervical dystonia/spasmodic torticollis.
      • Blepharospasm.
    • Member is at least 18 years of age.
    • Dose is appropriate for the stated indication.

    Upper-Limb Spasticity

    Xeomin is covered for upper-limb spasticity when ALL criteria are met:

    ALL of the following

    • Diagnosis of upper-limb spasticity.
    • Member is at least 2 years of age.
    • Appropriate dosing; for pediatric members, the prescriber must provide the child's weight.

    Sialorrhea

    Xeomin is covered for sialorrhea when ALL criteria are met:

    ALL of the following

    • Diagnosis of sialorrhea.
    • Member is at least 2 years of age.
    • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following

      • Scopolamine.
      • Glycopyrrolate.
      • Atropine.

    Other Indications and High-Dose Requests

    All other conditions and doses exceeding the limits in these criteria are reviewed case by case. A risk-benefit assessment should precede any decision to use an unlabeled indication, and the member should be established as unresponsive to conventional treatment options.

    ALL of the following

    • The requested condition or dose is not otherwise addressed by the applicable criteria, or the requested dose exceeds an established limit.
    • A case-by-case risk-benefit assessment supports the requested treatment.
    • For an unlabeled indication, the member is unresponsive to conventional treatment options.

    The Plan will not cover Botox, Dysport, Myobloc, or Xeomin for cosmetic conditions including facial rhytids, frown lines, glabellar wrinkling, horizontal neck rhytids, hyperfunctional facial lines, mid- and lower-face and neck rejuvenation, platysmal bands, rejuvenation of the periorbital region, or lateral canthal lines (crow's feet).

    Botox Cosmetic is excluded from coverage.

    Dysport 300 units (abobotulinumtoxinA) for glabellar lines is excluded from coverage.

    Clinical Dosing and Coding Details

    Chronic migraine frequency
    ConditionChronic migraine prophylaxis
    Minimum frequency≥ 15 headache days per month
    Dose requirementDose must be appropriate for the stated indication
    Adult neurogenic bladder escalation
    IndicationAdult neurogenic bladder dysfunction or neurogenic detrusor overactivity
    Escalated dose300 units
    Interval and prerequisiteNo more frequently than every 12 weeks after inadequate response to 200 units

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Botox, Daxxify, Dysport, Myobloc, and Xeomin under the MassHealth Unified Preferred Products List. Authorization applies under both the medical and pharmacy benefits.

    • Submit requests through the applicable medical-benefit or pharmacy-benefit authorization channel.
    • Medical benefit: 833-895-2611; fax 888-656-6671. Pharmacy benefit: 800-711-4555; fax 844-403-1029.
    Prior Authorization

    Initial Authorization and Request Scope

    Initial authorization is for the first course of therapy and is generally granted for 3 months. Requests must identify the indication, requested product and dose, and whether the request is for initial treatment, reauthorization, or a nonstandard use.

    • Individual product criteria must be met where applicable.
    • Unlisted indications and doses exceeding policy limits require case-by-case review.

    Policy Background

    Botulinum neurotoxins are used for focal muscle overactivity, dystonia, spasticity, bladder dysfunction, migraine prevention, hyperhidrosis, sialorrhea, and selected off-label conditions. Coverage depends on the specific product, indication, member age, requested dose, prescriber qualifications, and prior treatment response. The policy includes labeled and off-label indications; uses outside the stated criteria require a risk-benefit assessment.

    Definitions and Interpretation

    Overactive bladder
    SymptomUrinary urgency, with or without incontinence
    Additional symptomsNocturia or urinary frequency
    Review pathwayMay be reviewed using the overactive bladder criteria
    Partial CGRP inhibitor response
    Use caseMigraine prophylaxis in combination with a CGRP inhibitor
    Required responsePartial but incomplete response to the CGRP inhibitor
    Coverage contextIndividual drug prior authorization criteria must be met first where applicable

    Initial Therapy Criteria

    Botox Initial Therapy

    Botox initial therapy is covered when the applicable indication-specific criteria are met.

    Indication-specific Botox authorization: The requested diagnosis, prescriber specialty, prerequisite-treatment history, dosing, age, and any required specialist consultation or physician attestation meet the criteria for the requested indication.

    Apply the detailed Botox criteria for the requested indication.

    Product-Specific Initial Therapy

    Each product requires the applicable product-specific diagnosis, age, treatment history, and dosing criteria.

    Daxxify: Cervical dystonia or spasmodic torticollis; age at least 18 years; appropriate dosing; and requested dose no more than 500 units as a single dose.
    Dysport:

    Continuation Criteria

    Continuation Requirements

    Continuation authorization requires documentation of treatment response.

    Continuation response: The resubmission documents positive response to therapy. Migraine prophylaxis used with a CGRP inhibitor also requires improvement in headache days per month; gastroparesis requires documented positive response; all other indications require physician attestation of positive response.

    Migraine Prophylaxis Continuation

    Reauthorization requires documented clinical benefit.

    Migraine prophylaxis with a CGRP inhibitor: Resubmission documents positive response to therapy and improvement in headache days per month.Improvement in headache days per month

    Gastroparesis Continuation

    Step Therapy Requirements

    StepRequired prerequisite therapyRequirement
    1Beta blocker, tricyclic antidepressant, topiramate, and valproateInadequate response or adverse reaction to two agents, or contraindication to all listed agents. Beta-blocker exceptions apply for specified conditions including depression, asthma or bronchospastic disease, COPD, peripheral vascular disease, Raynaud’s, baseline hypotension or bradycardia, and pheochromocytoma.
    2Aimovig, Ajovy, Emgality, Nurtec, and QuliptaInadequate response or adverse reaction to one agent, or contraindication to all listed agents, before Botox chronic migraine prophylaxis.
    StepRequired prerequisite therapyRequirement
    1Overactive bladder: two anticholinergic medications, or one anticholinergic medication plus one beta-3 adrenergic receptor agonist such as mirabegronDocument inadequate response or adverse reaction to the required therapy, or contraindication to both listed classes.
    1Adult neurogenic bladder dysfunction or neurogenic detrusor overactivity: two anticholinergics; one anticholinergic plus one alpha blocker such as prazosin or terazosin; or one anticholinergic plus one cholinergic agent such as bethanecholDocument inadequate response or adverse reaction to the required regimen, or contraindication to all listed options. The 300-unit pathway additionally requires inadequate response to 200 units.
    1Pediatric neurogenic bladder dysfunction or neurogenic detrusor overactivity: one anticholinergic such as oxybutynin or solifenacin, or one beta-3 adrenergic receptor agonist such as mirabegronDocument inadequate response or adverse reaction to the required therapy, or contraindication to both listed classes.
    StepRequired prerequisite therapyRequirement
    1Aluminum chloride solutionFor severe primary axillary, palmar, or plantar hyperhidrosis, document physician-attested inadequate response, adverse reaction, or contraindication.
    1FDA-approved Botox dosing of 50 units per axillaFor escalated axillary dosing, document inadequate response to 50 units per axilla.
    StepIndicationRequired prerequisite therapy
    1Achalasia or esophageal dysphagiaFailure of a surgical option, such as pneumatic dilation, laparoscopic Heller myotomy with partial fundoplication, or POEM; or documentation that the member is not a surgical candidate or is unwilling to undergo surgery.
    1Pediatric chronic constipationInadequate response or adverse reaction to two laxatives, or contraindication to all laxatives; and inadequate response to dietary changes and/or behavior modification.
    1SialorrheaInadequate response or adverse reaction to two agents, or contraindication to all of atropine, glycopyrrolate, hyoscyamine, scopolamine, and a tricyclic antidepressant. Botox requests also require inadequate response, adverse reaction, or contraindication to both Myobloc and Xeomin.
    1Migraine prophylaxis with a CGRP inhibitorIndividual drug prior authorization criteria must be met; document a partial but incomplete response to the CGRP inhibitor and appropriate Botox dosing.
    StepIndication or productRequired prerequisite therapy
    1Myofascial pain syndromeInadequate response or adverse reaction to two, or contraindication to all, of cyclobenzaprine, gabapentin or pregabalin, a local anesthetic, an SNRI, and a tricyclic antidepressant.
    1Myofascial pelvic pain syndromeInadequate response, adverse reaction, or contraindication to two, or contraindication to all, of gabapentin or pregabalin, a muscle relaxant, an SNRI, a tricyclic antidepressant, and vaginal diazepam.
    1Anal fissuresInadequate response or adverse reaction to topical nifedipine or contraindication to both topical nifedipine and topical nitroglycerin.
    1GastroparesisInadequate response, adverse reaction, or contraindication to both metoclopramide and erythromycin; and inadequate response or adverse reaction to one antiemetic, or contraindication to all antiemetics.
    1Raynaud’s phenomenonInadequate response or adverse reaction to three, or contraindication to all, of a calcium channel blocker, fluoxetine, losartan, a PDE-5 inhibitor, and a topical nitrate.
    1Trigeminal neuralgiaInadequate response or adverse reaction to two, or contraindication to all, of baclofen, carbamazepine, gabapentin, lamotrigine, oxcarbazepine, tizanidine, and topiramate.
    1Severe craniofacial hyperhidrosisInadequate response or adverse reaction to one, or contraindication to all, of aluminum chloride solution, oral glycopyrrolate, and oral oxybutynin.
    1Thoracic outlet syndromeInadequate response or adverse reaction to two, or contraindication to all, of anesthetic injection, muscle relaxant, NSAID, and steroid injection; symptoms must persist despite physical therapy.
    1Dysport anal fissuresInadequate response or adverse reaction to topical nifedipine, or contraindication to both topical nifedipine and topical nitroglycerin.
    1Myobloc or Xeomin product-specific usesFor sialorrhea, document the required inadequate response, adverse reaction, or contraindication to the listed conventional agents. Other product-specific criteria require the applicable indication, age, and dosing requirements.
    StepRequired prerequisite therapyRequirement
    1Scopolamine, glycopyrrolate, atropine, hyoscyamine, and a tricyclic antidepressant such as amitriptyline or nortriptylineFor sialorrhea, document inadequate response or an adverse reaction to two agents, or a contraindication to all listed agents.
    StepRequired prerequisite therapyRequirement
    1A CGRP inhibitorDocument a trial with inadequate or partial but incomplete response, as applicable, before Botox chronic migraine therapy.
    2One step-through option, including beta blockersUse one of the multiple specified step-through options for chronic migraine therapy; beta blockers are included among the available options.
    StepRequired prerequisite therapyRequirement
    1ErythromycinFor off-label gastroparesis treatment, document a trial of erythromycin before Botox authorization.

    Quantity and Dose Limits

    Botox — achalasia quantity limit
    ProductBotox
    IndicationAchalasia or esophageal dysphagia
    Quantity limit≤ 100 units no more frequently than every six months
    Botox — pediatric chronic constipation quantity limit
    ProductBotox
    IndicationPediatric chronic constipation
    Quantity limit≤ 100 units no more frequently than every three months
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyNeuromuscular Blockers: Botox, Daxxify, Dysport, Myobloc, and Xeomin
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the diagnosis, requested dose and frequency, relevant age and weight information, prescriber specialty or consultation notes, and required prerequisite-treatment documentation.
    SourceLink
    On This Page
    Coverage CriteriaClinical Dosing and Coding DetailsProvider Actions and Authorization RequirementsPolicy BackgroundDefinitions and InterpretationInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsQuantity and Dose Limits
  1. Tricyclic antidepressant.
  2. Topiramate.
  3. Valproate, including valproic acid or divalproex.
  4. Inadequate response or adverse reaction to ONE, or contraindication to ALL, of the following CGRP-directed agents

    • Aimovig.
    • Ajovy.
    • Emgality.
    • Nurtec.
    • Qulipta.
  5. Dose is appropriate for the stated indication; see the Appendix for 10-week dosing.
  6. Dose is appropriate for the stated indication.
  7. Neurogenic bladder dysfunction/neurogenic detrusor overactivity—adults

    • Diagnosis of neurogenic bladder dysfunction or neurogenic detrusor overactivity.
    • Prescriber is a urologist or consult notes from a urologist are provided.
    • Inadequate response or adverse reaction to ONE, or contraindication to ALL, of the following

      • Two anticholinergic medications, such as oxybutynin or tolterodine.
      • One anticholinergic medication and one alpha blocker, such as prazosin or terazosin.
      • One anticholinergic medication and one cholinergic agent, such as bethanechol.
    • ONE of the following dosing requirements

      • Dose is appropriate for the stated indication.
      • Request is for 300 units no more frequently than every 12 weeks, and there has been an inadequate response to 200 units.
  8. Neurogenic bladder dysfunction/neurogenic detrusor overactivity—pediatrics

    • Diagnosis of neurogenic bladder dysfunction or neurogenic detrusor overactivity.
    • Prescriber is a urologist or consult notes from a urologist are provided.
    • Inadequate response or adverse reaction to ONE, or contraindication to BOTH, of the following

      • One anticholinergic medication, such as oxybutynin or solifenacin.
      • One beta-3 adrenergic receptor agonist, such as mirabegron.
    • Dose is appropriate for the stated indication and is administered no more frequently than every 12 weeks.
  9. Initial requested dose is no more than 100 units and no more frequently than every six months.<= 100 units every 6 months
  10. Pediatric chronic constipation

    • Diagnosis of pediatric chronic constipation.
    • Member is younger than 18 years of age.
    • Prescriber is a gastroenterologist or surgeon, or consult notes from one are provided.
    • Inadequate response or adverse reaction to TWO laxatives, or contraindication to ALL laxatives.
    • Inadequate response to dietary changes, such as increased fluids and fiber, and/or behavior modification, such as biofeedback or toilet training.
    • Initial requested dose is no more than 100 units and no more frequently than every three months.<= 100 units every 3 months
  11. Sialorrhea

    • Diagnosis of sialorrhea.
    • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following

      • Atropine.
      • Glycopyrrolate.
      • Hyoscyamine.
      • Scopolamine.
      • Tricyclic antidepressant, such as amitriptyline or nortriptyline.
    • Appropriate dosing: 40 to 100 units every three to six months.40–100 units every 3–6 months
    • Inadequate response, adverse reaction, or contraindication to both Myobloc and Xeomin.
  12. Migraine prophylaxis in combination with a CGRP inhibitor

    • Individual drug prior authorization criteria must be met first where applicable.
    • Diagnosis of migraine prophylaxis.
    • Partial, but incomplete, response to a CGRP inhibitor.
    • Appropriate dosing, including dosing every 10 weeks when applicable.
  13. SNRI, such as duloxetine.
  14. Tricyclic antidepressant, such as amitriptyline.
  15. Appropriate dosing up to a total dose of 200 units.<= 200 units
  16. Myofascial pelvic pain syndrome

    • Diagnosis of myofascial pelvic pain syndrome.
    • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following

      • Gabapentin or pregabalin.
      • Muscle relaxant, such as cyclobenzaprine.
      • SNRI, such as duloxetine.
      • Tricyclic antidepressant, such as amitriptyline.
      • Vaginal diazepam.
    • Appropriate dosing up to a total dose of 300 units.<= 300 units
  17. Anal fissures

    • Diagnosis of anal fissures.
    • Prescriber is a gastroenterologist or surgeon, or consult notes from one are provided.
    • Inadequate response or adverse reaction to ONE, or contraindication to BOTH, of the following

      • Topical nifedipine product.
      • Topical nitroglycerin.
    • Requested dose is no more than 100 units no more frequently than every 12 weeks.<= 100 units every 12 weeks
  18. Gastroparesis

    • Diagnosis of gastroparesis.
    • Prescriber is a gastroenterologist or surgeon, or consult notes from one are provided.
    • Inadequate response, adverse reaction, or contraindication to both metoclopramide and erythromycin.
    • Inadequate response or adverse reaction to ONE antiemetic, or contraindication to ALL antiemetics.
    • Requested dose is no more than 200 units no more frequently than every 12 weeks.<= 200 units every 12 weeks
  19. Raynaud's phenomenon

    • Diagnosis of Raynaud's phenomenon.
    • Inadequate response or adverse reaction to THREE, or contraindication to ALL, of the following

      • Calcium channel blocker, such as amlodipine or nifedipine.
      • Fluoxetine.
      • Losartan.
      • Phosphodiesterase type 5 inhibitor.
      • Topical nitrate.
    • Requested dose is no more than 200 units per 90 days.<= 200 units/90 days
  20. Trigeminal neuralgia

    • Diagnosis of trigeminal neuralgia.
    • Prescriber is a neurologist or physical medicine and rehabilitation physician, or consult notes from a specialist are provided.
    • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following

      • Baclofen.
      • Carbamazepine.
      • Gabapentin.
      • Lamotrigine.
      • Oxcarbazepine.
      • Tizanidine.
      • Topiramate.
    • Appropriate dosing, using FDA-approved dosing as a reference.
  21. Severe craniofacial hyperhidrosis

    • Diagnosis of severe craniofacial hyperhidrosis.
    • Prescriber is a dermatologist or neurologist, or consult notes from one are provided.
    • Inadequate response or adverse reaction to ONE, or contraindication to ALL, of the following

      • Aluminum chloride solution.
      • Oral glycopyrrolate.
      • Oral oxybutynin.
    • Appropriate dosing.
  22. Thoracic outlet syndrome

    • Diagnosis of thoracic outlet syndrome.
    • Member remains symptomatic despite physical therapy.
    • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following

      • Anesthetic injection, such as bupivacaine, lidocaine, or ropivacaine.
      • Muscle relaxant, such as cyclobenzaprine.
      • NSAID.
      • Steroid injection, such as triamcinolone.
    • Requested dose is no more than 100 units per 90 days.<= 100 units/90 days
  23. Ventral hernia

    • Diagnosis of ventral hernia.
    • Member has a surgical procedure scheduled to treat the ventral hernia.
    • Facial defect size is at least 5 cm as either a single defect or the summed size of defects.
    • Requested dose is no more than 500 units as a single dose.<= 500 units single dose
  24. Diagnosis of cervical dystonia/spasmodic torticollis.
  25. Member is at least 18 years of age.
  26. Dose is appropriate for the stated indication.
  27. Spasticity

    • Diagnosis of ONE of the following

      • Upper-limb spasticity.
      • Lower-limb spasticity.
    • Member is at least 2 years of age.
    • Dose is appropriate for the stated indication; for a child, the prescriber must provide the child's weight.
  28. Achalasia/esophageal dysphagia

    • Diagnosis of achalasia or esophageal dysphagia.
    • Prescriber is a gastroenterologist or surgeon, or consult notes from one are provided.
    • ANY of the following

      • Member has failed a surgical option, such as pneumatic dilation, laparoscopic Heller myotomy with partial fundoplication, or POEM.
      • Member is not a surgical candidate or is unwilling to undergo these procedures.
    • Initial requested dose is no more than 250 units and no more frequently than every six months.<= 250 units every 6 months
  29. Anal fissures

    • Diagnosis of anal fissures.
    • Prescriber is a gastroenterologist or surgeon, or consult notes from one are provided.
    • Inadequate response or adverse reaction to ONE, or contraindication to BOTH, of the following

      • Topical nifedipine product.
      • Topical nitroglycerin.
    • Requested dose is no more than 100 units no more frequently than every 12 weeks.<= 100 units every 12 weeks
  30. Myobloc (rimabotulinumtoxinB)—applicable indication

    • Cervical dystonia/spasmodic torticollis

      • Diagnosis of cervical dystonia/spasmodic torticollis.
      • Member is at least 18 years of age.
      • Dose is appropriate for the stated indication and is no more than 500 units as a single dose.<= 500 units single dose
    • Sialorrhea (salivary hypersecretion)

      • Diagnosis of sialorrhea.
      • Member is at least 18 years of age.
      • Inadequate response or adverse reaction to TWO, or contraindication to ALL, of the following

        • Scopolamine.
        • Glycopyrrolate.
        • Atropine.
        • Hyoscyamine.
        • Tricyclic antidepressant, such as amitriptyline or nortriptyline.
      • Dose is appropriate for the stated indication.
  31. Hyoscyamine.
  32. Tricyclic antidepressant, such as amitriptyline or nortriptyline.
  33. Dose is appropriate for the stated indication; for pediatric members, the prescriber must provide the child's weight.
  34. Axillary hyperhidrosis escalated dosing
    IndicationSevere axillary hyperhidrosis
    Prior doseFDA-approved dosing of 50 units per axilla
    Escalation prerequisiteInadequate response to the FDA-approved dose
    Achalasia initial dose
    IndicationAchalasia or esophageal dysphagia
    Initial dose≤ 100 units
    Frequency limitNo more frequently than every six months
    Pediatric chronic constipation initial dose
    IndicationPediatric chronic constipation
    Age requirementMember is younger than 18 years
    Initial dose and frequency≤ 100 units no more frequently than every three months
    Sialorrhea dosing
    IndicationSialorrhea
    Dose range40 to 100 units
    Treatment intervalEvery 3 to 6 months
    Myofascial pain syndrome dose
    IndicationMyofascial pain syndrome
    Total dose limitUp to 200 units total
    Treatment basisDose must be appropriate for the indication
    Myofascial pelvic pain syndrome dose
    IndicationMyofascial pelvic pain syndrome
    Total dose limitUp to 300 units total
    Treatment basisDose must be appropriate for the indication
    Anal fissure dose
    IndicationAnal fissures
    Dose limit≤ 100 units
    Frequency limitNo more frequently than every 12 weeks
    Gastroparesis and Raynaud’s dosing
    Gastroparesis dose≤ 200 units no more frequently than every 12 weeks
    Raynaud’s phenomenon dose≤ 200 units per 90 days
    IndicationsGastroparesis and Raynaud’s phenomenon
    Thoracic outlet syndrome dose
    IndicationThoracic outlet syndrome
    Dose limit≤ 100 units
    PeriodPer 90 days
    Selected product single-dose limit
    Applicable product criterionSelected product-specific requests
    Single-dose limit≤ 500 units
    Dose basisAs a single dose
    Standard single-dose threshold
    Applicable productsNeuromuscular blocker products
    Standard threshold≤ 500 units
    Administration basisAs a single dose
    Adult Botox high-dose maximum
    ProductBotox (onabotulinumtoxinA)
    PopulationAdults
    Maximum approvable doseUp to 840 units
    Pediatric Botox high-dose maximum
    ProductBotox (onabotulinumtoxinA)
    Weight-based maximumUp to 25 units/kg
    Total maximumUp to 600 units
    Adult Dysport high-dose maximum
    ProductDysport (abobotulinumtoxinA)
    PopulationAdults
    Maximum approvable doseUp to 1,500 units
    Pediatric Dysport high-dose maximum
    ProductDysport (abobotulinumtoxinA)
    Weight-based maximumUp to 25 units/kg
    Total maximumUp to 1,000 units
    Adult Myobloc high-dose maximum
    ProductMyobloc (rimabotulinumtoxinB)
    PopulationAdults
    Maximum approvable doseUp to 25,000 units
    Pediatric Myobloc high-dose maximum
    ProductMyobloc (rimabotulinumtoxinB)
    Weight-based maximumUp to 400 units/kg
    Total maximumUp to 10,000 units
    Adult Xeomin high-dose maximum
    ProductXeomin (incobotulinumtoxinA)
    PopulationAdults
    Maximum approvable doseUp to 840 units
    Note

    Reauthorization Duration

    Reauthorization duration depends on the indication and treatment context.

    • Migraine prophylaxis in combination with a CGRP inhibitor: 6 months.
    • Gastroparesis: 12 months.
    • All other indications: 12 months.
    Step Therapy

    Indication-Specific Prerequisite Therapy

    Document the required history of conventional treatment for the requested indication. Depending on the condition, the policy requires inadequate response, adverse reaction, or contraindication to specified therapies before botulinum toxin authorization.

    • Examples include migraine preventive therapies and CGRP agents; bladder anticholinergic, beta-3 agonist, alpha-blocker, or cholinergic therapy; aluminum chloride for hyperhidrosis; laxatives, dietary or behavioral interventions for pediatric constipation; and condition-specific therapies for achalasia, myofascial pain, anal fissures, gastroparesis, Raynaud’s phenomenon, trigeminal neuralgia, craniofacial hyperhidrosis, thoracic outlet syndrome, and other covered or reviewed indications.
    • Provide the specific agents tried, treatment response, adverse reactions, contraindications, and relevant treatment dates or clinical rationale.
    Step Therapy

    Sialorrhea Prerequisite Therapy

    For sialorrhea, document inadequate response or adverse reaction to the required conventional agents, or contraindication to all applicable alternatives.

    • Required agents may include atropine, glycopyrrolate, hyoscyamine, scopolamine, and a tricyclic antidepressant.
    • For Myobloc, document inadequate response, adverse reaction, or contraindication to two or all applicable agents.
    • For Xeomin, provide physician attestation supporting the treatment history.
    Documentation Required

    Current Treatment Documentation for New Members

    For members enrolled in the plan for 90 days or less, submit medical records showing that the member is currently receiving the requested drug. This exception does not apply when the product was obtained as samples or through a manufacturer’s patient assistance program.

    • Include the coverage effective date or other documentation establishing enrollment duration.
    • Records should identify the requested product, current dose, indication, and ongoing treatment.
    Documentation Required

    Clinical Records Supporting Initial Authorization

    Submit clinical records supporting the requested product and indication. Records must establish the diagnosis, requested dose, member age when relevant, prescribing specialty or consultation, and the clinical facts supporting medical necessity.

    • Include office notes, diagnostic findings, treatment history, and relevant specialist consultation notes.
    • Document specialty requirements, such as neurology, pain medicine/anesthesiology, physical medicine and rehabilitation, urology, dermatology, gastroenterology, surgery, or other specialty specified for the indication.
    • Include the product, indication, dose, frequency, age, and any required severity or symptom-frequency measures.
    Documentation Required

    Dose Documentation

    Document that the requested dose and frequency are appropriate for the indication. Pediatric requests require the child’s weight; high-dose requests require the documentation specified in the appendix.

    • Include the member’s current weight for pediatric dosing, including pediatric upper-limb spasticity and sialorrhea requests.
    • For requests involving 300 units, 500 units, escalated dosing, or other policy limits, document the applicable dose history, response, and frequency.
    • Use FDA-approved dosing or the indication-specific limits in the policy when applicable.
    Documentation Required

    Continuation Documentation

    For continuation requests, submit documentation of a positive response to therapy. Reauthorization requests must include a physician attestation of continued benefit unless the indication-specific requirements below call for additional measures.

    • For gastroparesis, document positive response to therapy.
    • For all other indications, provide physician attestation of a positive response.
    Documentation Required

    Pediatric Weight Documentation

    For pediatric upper-limb spasticity, provide the member’s weight to support the requested dose and confirm that the member meets the applicable age and indication criteria.

    • Document diagnosis of upper-limb spasticity.
    • Document that the member is at least 2 years of age.
    • Include the requested dose and weight-based dosing rationale.
    Documentation Required

    Sialorrhea Treatment-History Documentation

    For pediatric sialorrhea, submit the treatment history and the required physician attestation, together with the member’s weight when required for dosing.

    • Document diagnosis of sialorrhea and that the member is at least 2 years of age.
    • Attest to inadequate response or adverse reaction to two agents, or contraindication to all applicable agents.
    • Provide the child’s weight and requested dose.
    Documentation Required

    Continuation Response Documentation

    For migraine prophylaxis in combination with a CGRP inhibitor, the resubmission must demonstrate a positive response and improvement in headache days per month.

    • Report baseline and current headache days per month.
    • Document the member’s partial or positive response to the CGRP inhibitor and botulinum toxin regimen.
    Documentation Required

    Continuation Response Measures

    A continuation request is stronger when it includes measurable clinical improvement, not merely continued use of the product.

    • For migraine prophylaxis, document improvement in headache days per month.
    • For gastroparesis and other indications, describe the positive response and functional or symptom improvement in the physician attestation.
    Denial Risk

    Missing Criteria or Unsupported Use

    Requests may be denied when required information is missing or when the submitted records do not support the requested use. Authorization is not available solely because the product has been prescribed.

    • Common deficiencies include missing diagnosis, dose, age, weight, specialty records, treatment history, response documentation, or physician attestation.
    • Requests for unsupported, unlisted, or excessive use require case-by-case risk-benefit review and may be denied.
    Denial Risk

    Product-Specific Criteria Not Met

    Requests may be denied when product-specific criteria are not met, including the required indication, age, dose, prescriber specialty, conventional-treatment history, or supporting records.

    • Verify that the requested product’s criteria—not merely criteria for another botulinum toxin product—are satisfied.
    • Document all required prerequisite therapies, contraindications, specialist involvement, age thresholds, dosing limits, and indication-specific findings.
    • Failure to meet any required criterion may result in denial.
    Denial Risk

    Cosmetic and Facial Rejuvenation Exclusions

    The plan excludes cosmetic and facial-rejuvenation uses of Botox, Dysport, Myobloc, and Xeomin.

    • Excluded uses include facial rhytids, frown lines, glabellar wrinkling, horizontal neck rhytids, hyperfunctional facial lines, mid- and lower-face or neck rejuvenation, platysmal bands, periorbital rejuvenation, and lateral canthal lines (crow’s feet).
    Denial Risk

    Botox Cosmetic Exclusion

    Botox Cosmetic is explicitly excluded from coverage.

    • Do not submit Botox Cosmetic as a covered medical-benefit treatment.
    Denial Risk

    Dysport Glabellar-Line Exclusion

    Dysport 300 units (abobotulinumtoxinA) for glabellar lines is explicitly excluded.

    • Requests for this product, dose, and cosmetic indication are not covered.
    Note

    Unlisted Indications or Excessive Doses

    All other conditions and doses exceeding the stated limits are reviewed case by case. Before requesting an unlisted indication, establish that conventional treatment options have been unsuccessful or unsuitable and provide a risk-benefit rationale.

    • Include the diagnosis, clinical rationale, requested dose and frequency, prior conventional treatment, and supporting specialist records.
    • Risk-benefit assessment should precede use in an unlabeled indication.
    Continuation therapy
    Basis for continuationPositive response to therapy
    Migraine prophylaxis with a CGRP inhibitorDocument improvement in headache days per month
    Other indicationsPhysician attestation of positive response is required
    Cervical dystonia or spasmodic torticollis in a member at least 18 years old with appropriate dosing; upper- or lower-limb spasticity in a member at least 2 years old with appropriate dosing; or qualifying achalasia/esophageal dysphagia or anal fissure criteria.
    Myobloc: Cervical dystonia or spasmodic torticollis in a member at least 18 years old with appropriate dosing, or sialorrhea in a member at least 18 years old after the required treatment history.
    Xeomin: Cervical dystonia, spasmodic torticollis, or blepharospasm in a member at least 18 years old with appropriate dosing; upper-limb spasticity in a member at least 2 years old; or sialorrhea in a member at least 2 years old after the required treatment history.

    Xeomin Neurologic Indications

    Initial coverage requires all of the following.

    Xeomin neurologic indications: Diagnosis is cervical dystonia, spasmodic torticollis, or blepharospasm; member is at least 18 years old; and dosing is appropriate for the stated indication.Age >= 18 years

    Upper-Limb Spasticity

    Initial coverage requires all of the following.

    Upper-limb spasticity: Diagnosis of upper-limb spasticity; member is at least 2 years old; and dosing is appropriate for the indication.Age >= 2 years

    Provide the child's weight for pediatric dosing review.

    Sialorrhea

    Initial coverage requires all of the following.

    Sialorrhea: Diagnosis of sialorrhea; member is at least 2 years old; inadequate response or adverse reaction to two, or contraindication to all, of scopolamine, glycopyrrolate, atropine, hyoscyamine, and a tricyclic antidepressant; and dosing is appropriate.Age >= 2 years

    Provide the child's weight for pediatric dosing review.

    Reauthorization requires documented clinical benefit.

    Gastroparesis: Resubmission documents positive response to therapy.Positive response

    Continuation for All Other Indications

    Reauthorization requires documented clinical benefit.

    All other indications: The physician attests to a positive response to therapy.Positive response

    Applies to indications other than migraine prophylaxis with a CGRP inhibitor and gastroparesis.

    Botox — sialorrhea quantity limit
    ProductBotox
    IndicationSialorrhea
    Quantity limit40 to 100 units every 3 to 6 months
    Botox — myofascial pain syndrome quantity limit
    ProductBotox
    IndicationMyofascial pain syndrome
    Quantity limitUp to 200 units total
    Botox — myofascial pelvic pain syndrome quantity limit
    ProductBotox
    IndicationMyofascial pelvic pain syndrome
    Quantity limitUp to 300 units total
    Botox — gastroparesis and Raynaud’s quantity limits
    ProductBotox
    Gastroparesis limit≤ 200 units every 12 weeks
    Raynaud’s phenomenon limit≤ 200 units per 90 days
    Botox — thoracic outlet syndrome quantity limit
    ProductBotox
    IndicationThoracic outlet syndrome
    Quantity limit≤ 100 units per 90 days
    Daxxify — single-dose quantity limit
    ProductDaxxify
    IndicationCervical dystonia or spasmodic torticollis
    Quantity limit≤ 500 units as a single dose
    Dysport — achalasia/esophageal dysphagia and anal fissure quantity limits
    ProductDysport
    Achalasia or esophageal dysphagia≤ 250 units every six months
    Anal fissures≤ 100 units every 12 weeks
    Neuromuscular blocker products — standard single-dose threshold
    Applicable productsNeuromuscular blocker products
    Standard quantity threshold≤ 500 units
    Administration basisAs a single dose
    Botox (onabotulinumtoxinA), adults — high-dose maximum
    ProductBotox (onabotulinumtoxinA)
    PopulationAdults
    High-dose maximumUp to 840 units
    Dysport (abobotulinumtoxinA), adults — high-dose maximum
    ProductDysport (abobotulinumtoxinA)
    PopulationAdults
    High-dose maximumUp to 1,500 units
    Myobloc (rimabotulinumtoxinB), adults — high-dose maximum
    ProductMyobloc (rimabotulinumtoxinB)
    PopulationAdults
    High-dose maximumUp to 25,000 units
    Xeomin (incobotulinumtoxinA), adults — high-dose maximum
    ProductXeomin (incobotulinumtoxinA)
    PopulationAdults
    High-dose maximumUp to 840 units
    Botox — updated adult neurogenic bladder dose and interval
    ProductBotox
    IndicationAdult neurogenic bladder dysfunction or neurogenic detrusor overactivity
    Updated dose and interval300 units no more frequently than every 12 weeks